Serostim may be part of symptomatic management for severe, unwanted loss of body tissue and physical function associated with HIV-related wasting or cachexia in adult patients. The medication is relevant for easing symptoms that interfere with daily functioning, supporting improved physical endurance, and assisting with the management of lean body mass in adult patients with HIV-associated wasting or cachexia.

The medication is relevant in clinical settings that involve chronic, progressive tissue loss, and is applied for symptomatic relief related to progressive loss of lean body mass, diminished physical endurance, and unintentional body weight reduction. This application assists with maintaining a more manageable level of routine physical activity.

---

“This treatment helps ease the daily burden of weakness and fatigue, and assists with maintaining a more manageable level of routine physical activity.”

Therapeutic Benefit Summary

This medication is considered relevant for the management of severe, involuntary weight loss, a symptom associated with heightened physiological stress. It primarily helps relieve symptoms linked to a negative nitrogen balance, specifically the critical loss of muscle tissue integrity. By assisting with the management of lean body mass, Serostim contributes to improved functional capacity.

---

Quick Fact: Symptomatic Support The treatment is used in clinical scenarios where symptoms create noticeable physiological strain due to the severe, progressive depletion of muscle and tissue mass. It provides supportive relief that contributes to easing the overall symptom load during difficult episodes.

Serostim (somatropin) is indicated for the treatment of HIV-positive patients with wasting or cachexia to help increase lean body mass and body weight, and improve physical endurance. It is essential that patients receiving Serostim also be on concomitant antiretroviral therapy.

---

Contraindications

Serostim is not to be used in patients who meet the following criteria, as these conditions may increase the risk of serious adverse effects:

• Acute Critical Illness: This includes complications following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure.
• Active Malignancy: Somatropin is contraindicated in the presence of active cancer. Any preexisting malignancy must be inactive and its treatment complete prior to starting therapy.
• Diabetic Retinopathy: Specifically, active proliferative or severe non-proliferative diabetic retinopathy.
• Hypersensitivity: Known allergy to somatropin or any other ingredient in the formulation.

---

Other Important Considerations

Caution is advised for patients with a history of malignancy, diabetes, or impaired glucose tolerance, as growth hormone treatment can exacerbate these conditions. Blood glucose levels should be monitored closely. The safety and effectiveness of Serostim in pregnant or nursing mothers and pediatric HIV patients have not been fully established.

The regulatory interaction profile for Serostim (Somatropin) is defined by its effects on hormonal and metabolic pathways. Somatropin treatment can alter the clearance of co-administered medicines, including compounds metabolized by CYP450 liver enzymes, with evidence suggesting the potential to increase the clearance of CYP450 3A4 substrates such as certain sex steroids, anticonvulsants, and cyclosporine. Furthermore, the product is officially associated with reduced insulin sensitivity, a condition that requires careful consideration when co-administering insulin and oral/injectable hypoglycemic agents as a dose adjustment may be necessary.

Interactions with other hormones are explicitly documented. Somatropin inhibits the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1), which results in reduced serum cortisol concentrations. Separately, pharmacologic doses of glucocorticoids may attenuate the efficacy of somatropin. Additionally, in female patients receiving oral estrogen replacement, a larger somatropin dose may be required to achieve the established therapeutic outcome, a finding specific to the oral route of estrogen administration. Finally, all growth hormone products must be discontinued for a minimum of one week prior to administering the diagnostic agent macimorelin. This comprehensive profile reflects the product's classification as a hormonal agent.

Molecular Agonism of the Growth Hormone Axis

Somatropin acts as an agonist by binding to and activating the Growth Hormone Receptor (GHR) on target cells, which triggers the JAK-STAT signaling pathway inside. This molecular interaction leads to the systemic release of Insulin-like Growth Factor-I (IGF-I), which mediates many downstream physiological actions.

Metabolic Shift and Tissue Anabolism

Activation of the GHR-IGF-I axis drives a dual effect on metabolism: it increases protein synthesis (anabolism) in muscle tissue while decreasing protein breakdown (anticatabolism). This action also promotes protein-sparing lipid oxidation, wherein fat stores are preferentially used for energy. This mechanistic shift leads to a net accretion of Lean Body Mass (LBM) and a positive nitrogen balance.

Mechanistic Constraints

The biological mechanism of growth hormone is inherently counter-regulatory to insulin, leading to a temporary reduction in insulin sensitivity in peripheral tissues. Furthermore, the process of LBM gain involves the retention of intracellular fluid and specific minerals, which can cause transient tissue turgor as a physiological consequence of the primary anabolic effect.

Official Administration Instructions

Serostim (somatropin) is administered by subcutaneous injection and requires simultaneous use of concomitant antiretroviral therapy. The powder must be reconstituted prior to injection following specific preparation steps. The solution must be clear and colorless; if it appears cloudy or contains particulate matter, it must not be injected.

Dosing and Timing

The recommended dose is 0.1 mg/kg administered once daily, up to a maximum daily dose of 6 mg. This is typically given at bedtime. For patients with a body weight greater than 55 kg (121 lb), the dose is 6 mg SC daily. Patients at increased risk for adverse effects, such as glucose intolerance, should be considered for a starting dose of 0.1 mg/kg every other day. Dose reductions should be considered by a healthcare provider if side effects potentially related to growth hormone therapy occur.

Preparation and Procedure

1. Reconstitution: Inject the prescribed diluent (Sterile Water for Injection, USP for single-use vials, or Bacteriostatic Water for Injection, USP for multi-use vials) into the Serostim vial, aiming for the glass vial wall.
2. Mixing: Swirl the vial with a gentle rotary motion until the powder is completely dissolved. DO NOT SHAKE.
3. Injection: The injection must be given subcutaneously, and the sites (thigh, upper arm, abdomen, or buttock) should be rotated daily to prevent local irritation or lipoatrophy.

Missed Dose

If a dose is missed, patients must call their doctor or pharmacist for guidance. A double dose should never be injected to compensate for the missed one. The therapy must be conducted under the regular guidance of a physician experienced in managing HIV infection.

Research evidence / Overview of Studies for Serostim

---

Evidence for use in HIV-associated Wasting or Cachexia

The clinical evaluation of Serostim (Somatropin) was primarily conducted through short-term, randomized, double-blind, placebo-controlled trials (RCTs). These studies were used in research exploring the metrics of lean body mass (LBM) and physical function over defined time intervals in adult patients experiencing HIV-associated wasting or cachexia. These conditions are marked by functional limitations and physiological strain.

The main focus of these RCTs was to evaluate LBM and body weight measurements. Research also evaluated Physical Function, including work capacity and endurance metrics, assessed through standardized exercise tests. Studies examined patients who were generally receiving concomitant antiretroviral therapy.

---

Study Design and Measured Outcomes

In these trials, findings describe patterns observed in the studies where measurements of LBM and total body weight were higher compared to patients who received placebo. Research also recorded measurements of physical endurance, with some trials describing patterns observed in exercise testing.

Some trials also examined patient-reported outcomes describing perceived discomfort and health-related quality of life (HR-QOL). However, findings were mixed on HR-QOL when comparing the study groups, meaning certainty remains low on this specific outcome.

---

Long-term Studies and Follow-up

The most comprehensive controlled evidence focuses on the initial 12 to 24-week treatment period. To study outcomes over a longer time interval, patients were followed into open-label extension phases. However, there is insufficient data from controlled studies for long-term outcomes beyond 48 weeks. Therefore, the durability of patterns related to short-term measurements over multiple years is not yet established.

---

What is Still Uncertain About Serostim Research

Long-term effects on physical function and LBM maintenance are not fully established beyond the intermediate-term follow-up. Also, certain outcomes evaluated in the studies were not uniformly consistent; for example, findings for functional measures, such as grip strength, were mixed across different studies. The initial clinical trials focused on a specific, well-defined group of adults, meaning comparative evidence is lacking for many other potential patient groups.

Key Studies & References

1. Effect of recombinant human growth hormone on functional status and body composition in patients with AIDS and weight loss: a randomized, placebo-controlled trial.

Common questions about Serostim (FAQ)

Q: What should I do if I forget to take my daily dose of Serostim?

If you miss your daily injection, official product instructions state that you should not attempt to inject a double dose to make up for the missed one. The regulatory documents state that guidance for a missed dose should be obtained directly from a healthcare professional or pharmacist.

Q: What kind of water should I use to mix the Serostim powder for a single-use vial?

For single-use Serostim vials, the powder is reconstituted using Sterile Water for Injection, USP. The official product labeling specifies this diluent for this vial format, and the solution should be used immediately after preparation.

Q: How long are the clinical trials that established the effectiveness of Serostim?

Studies and official information indicate that the effectiveness of Serostim was established in short-term, controlled clinical trials that typically lasted between 12 and 24 weeks. Controlled data on the safety and efficacy of continuous use are not available for periods extending beyond 48 weeks.

Q: Can Serostim interact with other medications I am taking, like birth control or epilepsy drugs?

Official product information indicates that Serostim may interact with certain medications. It can increase the body's clearance rate of drugs metabolized by the CYP450 3A4 enzyme, which includes certain sex steroids (like those in oral birth control) and anticonvulsants (epilepsy drugs). This interaction may mean a dose adjustment of the co-administered drug is necessary.

Q: What is the difference in packaging or features between the single-use and multi-use Serostim vials?

Regulatory documents describe a difference based on the diluent provided. Single-use vials are generally packaged with Sterile Water for Injection. Multi-use vials are often packaged with Bacteriostatic Water for Injection, which includes a preservative that allows the mixed solution to be refrigerated and used for up to 14 days.

Q: If I develop nausea or vomiting while on Serostim, is this a recognized side effect?

While nausea and vomiting are not listed as common side effects, regulatory documents mention them as potential symptoms associated with a rare but serious adverse reaction called Intracranial Hypertension (increased pressure around the brain). Symptoms like these, especially when combined with a severe or persistent headache, should be immediately reported to a healthcare professional.

Q: Can I start Serostim immediately after recovering from a severe acute illness?

According to the official product information, Serostim is strictly contraindicated in patients with acute critical illness due to complications from severe trauma, surgery, or respiratory failure, as an increased risk of mortality has been reported. However, the label does not specify the time frame after recovery that must elapse before therapy can be initiated.

Official Storage and Disposal Instructions

Serostim (somatropin) must be stored under specific, labeled conditions to maintain its efficacy and safety profile.

Product Form	Storage Temperature (Mandatory)	Stability/Shelf-Life
Unreconstituted Powder	Refrigerate: 2 C to 8 C	Protect from freezing.
Reconstituted (Bacteriostatic Water)	Refrigerate: 2 C to 8 C	Stable for up to 14 days.
Reconstituted (Sterile Water)	N/A	Must be used immediately and any unused portion discarded.

Handling and Safety

During reconstitution, gently swirl the vial; do not shake the solution. The reconstituted product must be clear and colorless, without particulate matter. Store all medication and associated supplies out of the sight and reach of children in a secure location.

Disposal

Used needles, syringes, and vials must be immediately placed in a designated, puncture-resistant sharps container. Do not use household trash for sharps disposal. Consult a healthcare professional or pharmacist for instructions on proper disposal of the full sharps container.